Autopsy report · NCT03043651

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

“Terminated by Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 2 years 1 month before it stopped.
• 48 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

United Therapeutics

Sponsor type

Industry

Conditions

Pulmonary Hypertension Associated With HFpEF

Interventions

Oral treprostinil

Participants

48

Sites

82

Countries

United States

Trials that died the same way

• RibFix Advantage™ Post-Market Follow-Up
  “Sponsor Terminated” (96% match in meaning)
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (93% match in meaning)
• Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
  “Terminated by previous Sponsor decision” (92% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (91% match in meaning)
• Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
  “Terminated at the request of the financial sponsor.” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.